Interventions that activate this CD8+ T cell/TIM3/IL-13-to-macrophage/IL-10 pathway to boost endogenous pain resolution could provide a treatment for persistent CIPN, thereby improving quality of life of the growing number of cancer survivors. The gene discussed is IL10; the disease is cancer.